STAT3 and neoplasm: miR-223 significantly inhibits the differentiation and accumulation of MDSCs as well as their suppressive function by targeting myocyte enhancer factor 2C (MEF2C) and inhibiting STAT3 signaling respectively in tumor-bearing mice (72–74).